Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for October 20, 2021

10/20/2021

 
Regulatory Update
 
The FDA rejected daxibotulinumtoxinA due to deficiencies related to the FDA’s onsite inspection at Revance’s manufacturing facility.
 
The FDA rejected narsoplimab due to current data not supporting efficacy in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
 
The FDA delayed the PDUFA date for bimekizumab, because of COVID-19 pandemic restrictions preventing inspection of the UCB European manufacturing site for the drug.
 
Sage Therapeutics and Biogen intend to submit NDAs for zuranolone for the treatment of major depressive disorder (MDD) in the second half of 2022 and to treat postpartum depression (PPD) in the first half of 2023.
 
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of abrocitinib for the treatment of atopic dermatitis.
 
Announced Research Updates
 
Biogen announced that in the 28-week, 108 patient Phase III, VALOR trial, treatment with tofersen did not improve the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) compared to placebo in patients with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
 
Entasis announced that in the 28-day, 207 patient, Phase III, ATTACK trial, treatment with sulbactam/durlobactam resulted in 19% mortality compared to 32.3% with colistin in 125 patients with documented Acinetobacter baumannii infection. In a 28-day open-label portion of the trial, where all patients were treated with sulbactam/durlobactam, mortality was 17.9% in patients with Acinetobacter baumannii-calcoaceticus Complex infections that are resistant to or failed colistin or polymyxin B.
 
Dicerna announced that in the six patient, Phase I, PHYOX4 trial, a single dose of nedosiran was well tolerated, but did not result in a 30% or more decrease in 24-hour urine oxalate excretion on at least two consecutive visits over the three-month observation period in patients with primary hyperoxaluria type 3 (PH3).
 
Galera announced that in the 455 patient, Phase III, ROMAN trial, treatment with avasopasem did not decrease the incidence of severe oral mucositis compared to placebo in patients with locally advanced head and neck cancer receiving seven weeks of radiotherapy plus cisplatin.
 
Published Research Updates
 
In the 15-month, 323 patient, Phase III, PLEO-CMT trial, the highest dose of PXT3003 (6 mg baclofen, 0.7 mg naltrexone and 210 mg sorbitol) reduced the Overall Neuropathy Limitation Scale (ONLS) score by 0.37 points more than placebo in patients with mild to moderate Charcot-Marie-Tooth Type 1A Disease.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.